CD71 (Transferrin Receptor) Monoclonal Antibody (OKT9 (OKT-9)), eBioscience™, Invitrogen™

Description

Description: The OKT9 monoclonal antibody reacts with human CD71, a 170-180 kDa type II transmembrane protein. CD71, the transferrin receptor, exists as a homodimer on the cell surface and is essential for cellular growth. CD71 is expressed by immature proliferating cells and at low levels on resting mature lymphocytes. Antigen or mitogen stimulation of T and B cells upregulates the expression of CD71. Applications Reported: The OKT9 (OKT-9) antibody has been reported for use in flow cytometric analysis. Applications Tested: This OKT9 (OKT-9) antibody has been tested by flow cytometric analysis of unstimulated and CD3/CD28-stimulated (3 days) human blood cells. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes. Endosomal acidification leads to iron release. The apotransferrin-receptor complex is then recycled to the cell surface with a return to neutral pH and the concomitant loss of affinity of apotransferrin for its receptor. Transferrin receptor is necessary for development of erythrocytes and the nervous system. Serum transferrin receptor (sTfR) is used as a means of detecting erythropoietin (EPO) misuse by athletes and as a diagnostic test for anemias resulting from a number of conditions including rheumatoid arthritis, pregnancy, irritable bowel syndrome and in HIV patients.